Jun 28, 2021 7:00am EDT Can-Fite Enters Projected $3 Billion Veterinary Osteoarthritis Market: Signs Agreement with Vetbiolix for Development of Piclidenoson for Pets
Jun 02, 2021 7:35am EDT Can-Fite To Initiate Phase IIb NASH Study with its Drug Candidate Namodenoson
Jun 02, 2021 7:00am EDT Can-Fite to Present at BIO Digital International Convention & Conduct One-on-One Meetings with Potential Partners on June 10-18, 2021
May 27, 2021 7:00am EDT Can-Fite Reports First Quarter 2021 Financial Results & Provides Clinical Update
May 27, 2021 6:00am EDT Can-Fite BioPharma Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
May 06, 2021 7:00am EDT Can-Fite to Present at Benzinga’s Global Small Cap Conference on May 13, 2021
Apr 29, 2021 7:00am EDT Can-Fite’s Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021
